@Chickenandrice
Do we know when regeneron may be available for widespread use?
I was in error in my previous post. I saw an interview with Bill Gates about a month ago in which he stated that his foundation was funding antibody production because the US government hadn't. According to this
www.sciencemag.org/news/2020/09/provocative-results-boost-hopes-antibody-treatment-covid-19
Regeneron has since received $450 million from the government for 300,000 doses by year end.
And from here
www.washingtonpost.com/health/2020/09/30/monoclonal-antibodies-to-treat-covid-19/
To prepare for making the drug at scale, Regeneron transferred its other products to its facility in Ireland. It recently struck a deal with a competitor, Roche, to rapidly increase production.
“This is quite unusual, because we’re giving a competitor a lot of our know-how, our technology,” said Schleifer, the Regeneron CEO. “They’re going to get to drive our cars, so to speak.”
With the partnership, the companies can manufacture between 650,000 and 2 million treatment doses in a year, or 4 million to 8 million prevention doses. The United States has placed an order for $450 million worth of medicine — enough for 70,000 to 300,000 treatments, depending on how much of the drug is in each dose. But with the Centers for Disease Control and Prevention forecasting 1,500 to 5,000 hospitalized patients a day by late October, that supply could be rapidly consumed.
So it's going to be in short supply for quite a while. Eli Lilly's antibody cocktail will probably have similar benefits and it's being produced separately, so that will give more supply.